فرخ کریمی مندل بسر

Introduction: Ovarian cancer is the most common cause of death from gynecological cancer. Ovarian cancer is usually diagnosed at an advanced stage when survival rates are poor. Therefore, early detection strategies for ovarian cancer can greatly improve patient’s survival. Circulating cell-free RNA (cfRNA) hold enormous potential as a new class of biomarkers for the development of noninvasive liquid biopsies in cancers. cfRNAs are effective, sensitive and specific biomarkers for early detection of cancers. Liquid biopsy analyses of RNA can offer more sensitive diagnostic approaches. cfRNA is released into the circulation by cancer cells; cfRNA could enhance detection of tumors with low burden due to higher expression compared to cfDNA. cfRNA provides a good opportunity to predict and detect cancer in slow-growing tumors. Because the expression of tumor-specific transcripts is high which can lead to the amplification of cfRNA signals in the blood. Circulating cfRNA includes: messenger RNA (mRNA), miRNA, long-noncoding RNA (lncRNA), circular RNA (circ RNA) and other noncoding RNAs. Methods: In this project we compared three methods including RNX- Plus kit, TRIzol LS reagent (Sigma) and RiboExTM LS kit (GeneAll) for the extraction of cell-free RNA from plasma samples. Results: quality and quantity analysis of extracted cell free RNA indicated that the RiboExTM LS kit was optimal method for extracting high-quality cell-free RNA in the highest quantities possible. Conclusion: In conclusion the result of this study indicated that RiboExTM LS kit (GeneAll) protocol can be used as an optimal method for extraction of cfRNA from blood samples of ovarian cancer patients. cfRNAs are used in non-invasive methods for detection of ovarian cancer